<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00623779</url>
  </required_header>
  <id_info>
    <org_study_id>D1250C00051</org_study_id>
    <nct_id>NCT00623779</nct_id>
  </id_info>
  <brief_title>Atrial Fibrillation (AF) Patients Not Taking Vitamin-K Antagonist (VKA)</brief_title>
  <official_title>A Controlled, Randomized, Parallel , Multi-centre Feasibility Study of the Oral Direct Thrombin Inhibitor, AZD0837, Given as ER Formulation, in the Prevention of Stroke and Systolic Embolic Events in Patients With Atrial Fibrillation, Who Are Appropriate for But Unable/Unwilling to Take VKA Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability of AZD0837 in patients
      with atrial fibrillation who are unable or unwilling to take vitamin K antagonist therapy for
      up to 3 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Premature Discontinuation of Study or Study Drug Due to Any Reason</measure>
    <time_frame>28 week (randomisation visit to last follow up visit in study) according to protocols</time_frame>
    <description>The premature discontinuation of study or study drug due to any reason</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Premature Discontinuation of Study Drug Due to Any Reason</measure>
    <time_frame>24 weeks (randomisation visit to last treatment visit)</time_frame>
    <description>The premature discontinuation of study drug due to any reason</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Premature Discontinuation of Study Due to Any Reason</measure>
    <time_frame>28 weeks (randomisation visit to last follow up visit)</time_frame>
    <description>|The premature discontinuation of study due to any reason</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compliance With Study Drug</measure>
    <time_frame>24 weeks (randomisation visit to last treatment visit) according to protocol</time_frame>
    <description>[(number of doses dispensed-number of doses returned)/number of days between visits]*100</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compliance With Study Visits/Assessments</measure>
    <time_frame>28 weeks (randomisation visit to last follow up visit) according to protocol</time_frame>
    <description>(number of visits attended acroos the time of study divided by the number of expected visits according to the time of entry into study)*100</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding Events</measure>
    <time_frame>24 weeks (randomisation visit to last treatment visit) according to protocol. For patients who discontinued treatment the time frame was &lt;24 weeks. Mean number of weeks was 7 weeks (baseline to end of treatment visit)</time_frame>
    <description>Number of patients with a bleeding event while on study drug. Patients with multiple bleeding events are counted once</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Creatinine Level</measure>
    <time_frame>4 weeks according to protocol (randomisation visit to week 4 visit)</time_frame>
    <description>Individual change in Creatinine level (umil/L) from baseline to week 4 visit for patients while on study drug (week 4 visit-baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine Aminotransferase (ALAT)</measure>
    <time_frame>24 weeks (randomisation visit to last treatment visit) according to protocol. For patients who discontinued treatment the time frame was &lt;24 weeks. Mean number of weeks was 7 weeks (baseline to end of treatment visit)</time_frame>
    <description>Number of patients while on study drug with Alanine aminotransferase (ALAT)&gt;=3 times upper limit of normal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilirubin</measure>
    <time_frame>24 weeks (randomisation visit to last treatment visit) according to protocol. For patients who discontinued treatment the time frame was &lt;24 weeks. Mean number of weeks was 7 weeks (baseline to end of treatment visit)</time_frame>
    <description>Number of patients while on study drug with Bilirubin&gt;=2 times upper limit of normal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of AZD0837 (Prodrug)</measure>
    <time_frame>4 weeks after baseline according to protocol</time_frame>
    <description>Assessment of plasma concentration of AZD0837 (prodrug) made on the week 4 visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of AR-H067637XX (Active Metabolite)</measure>
    <time_frame>4 weeks after baseline according to protocol</time_frame>
    <description>Assessment of plasma concentration of AR-H067637XX (active metabolite) made on the week 4 visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in D-Dimer Level</measure>
    <time_frame>4 weeks according to protocol.(baseline to week 4 visit)</time_frame>
    <description>Individual change in D-Dimer level (ng/ml) from baseline to week 4 visit for patients while on study drug (week 4 visit-baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activated Partial Thromboplastin Time (APTT)</measure>
    <time_frame>4 weeks according to protocol.(baseline to week 4 visit)</time_frame>
    <description>Individual change in Activated partial thromboplastin time (APTT) (sec) from baseline to week 4 visit for patients while on study drug (week 4 visit-baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ecarin Clotting Time (ECT)</measure>
    <time_frame>4 weeks according to protocol.(baseline to week 4 visit)</time_frame>
    <description>Individual change in Ecarin clotting time (ECT) (sec) from baseline to week 4 visit for patients while on study drug (week 4 visit-baseline)</description>
  </secondary_outcome>
  <enrollment type="Actual">128</enrollment>
  <condition>Persistent or Permanent Non-valvular Atrial Fibrillation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD0837</intervention_name>
    <description>ER formulation</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Oral form</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Either one of the following risk factors is sufficient for inclusion (high risk
             patient)

          -  Previous cerebral ischaemic attack (stroke or transient ischaemic attack (TIA), &gt;30
             days prior to randomization)

          -  Previous systemic embolism or at least one of the following risk factors are needed
             for inclusion: Age â‰¥75 years

          -  Symptomatic congestive heart failure

          -  Impaired left ventricular systolic function

          -  Diabetes mellitus; Hypertension requiring anti-hypertensive treatment

          -  In addition to AF the patient must be appropriate for but unable or unwilling to take
             VKA therapy

        Exclusion Criteria:

          -  Presence of a clinically significant valvular heart disease;; Stroke or TIA and/or
             systemic embolism within the previous 30 days prior to randomization

          -  Conditions associated with increased risk of major bleeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory Y Lip, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Birmingham City Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Arhus N</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Esbjerg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frederikssund</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Horsens</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kobenhavn</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Silkeborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Svendborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Elverum</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gjettum</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kongsberg</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stovner</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Straume</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bytom</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Czestochowa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ostrow Mazowiecka</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Otwock</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plock</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ruda Slaska</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sopot</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Torun</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boras</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Goteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Malmo</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Molndal</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Eastbourne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2008</study_first_submitted>
  <study_first_submitted_qc>February 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2008</study_first_posted>
  <results_first_submitted>June 30, 2011</results_first_submitted>
  <results_first_submitted_qc>June 30, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 28, 2011</results_first_posted>
  <last_update_submitted>March 20, 2012</last_update_submitted>
  <last_update_submitted_qc>March 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study population included male and female participants &gt;18 years of age with chronic non-valvular Atrial Fibrillation. The participants were recruited during the time period from 22 October 2007 to 21 October 2008 at medical clinics in Europe.</recruitment_details>
      <pre_assignment_details>For participants treated with Vitamin K Antagonists (VKA) at the time of enrollment, VKA treatment was to be adjusted (and stopped before randomisation) to ensure that INR was below 2.0 at randomisation. If this was not achieved the participant was discontinued from the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AZD0837 150 mg</title>
          <description>AZD0837 150 mg</description>
        </group>
        <group group_id="P2">
          <title>AZD0837 300 mg</title>
          <description>AZD0837 300 mg</description>
        </group>
        <group group_id="P3">
          <title>Standard Therapy</title>
          <description>Standard Therapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="42"/>
                <participants group_id="P3" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Criteria from CSR</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AZD0837 150 mg</title>
          <description>AZD0837 150 mg</description>
        </group>
        <group group_id="B2">
          <title>AZD0837 300 mg</title>
          <description>AZD0837 300 mg</description>
        </group>
        <group group_id="B3">
          <title>Standard Therapy</title>
          <description>Standard Therapy</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
            <count group_id="B2" value="42"/>
            <count group_id="B3" value="45"/>
            <count group_id="B4" value="128"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.5" spread="8"/>
                    <measurement group_id="B2" value="71.6" spread="8.51"/>
                    <measurement group_id="B3" value="68.8" spread="9.36"/>
                    <measurement group_id="B4" value="70" spread="8.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Premature Discontinuation of Study or Study Drug Due to Any Reason</title>
        <description>The premature discontinuation of study or study drug due to any reason</description>
        <time_frame>28 week (randomisation visit to last follow up visit in study) according to protocols</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD0837 150 mg</title>
            <description>AZD0837 150 mg</description>
          </group>
          <group group_id="O2">
            <title>AZD0837 300 mg</title>
            <description>AZD0837 300 mg</description>
          </group>
          <group group_id="O3">
            <title>Standard Therapy</title>
            <description>Standard Therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Premature Discontinuation of Study or Study Drug Due to Any Reason</title>
          <description>The premature discontinuation of study or study drug due to any reason</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Premature Discontinuation of Study Drug Due to Any Reason</title>
        <description>The premature discontinuation of study drug due to any reason</description>
        <time_frame>24 weeks (randomisation visit to last treatment visit)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD0837 150 mg</title>
            <description>AZD0837 150 mg</description>
          </group>
          <group group_id="O2">
            <title>AZD0837 300 mg</title>
            <description>AZD0837 300 mg</description>
          </group>
          <group group_id="O3">
            <title>Standard Therapy</title>
            <description>Standard Therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Premature Discontinuation of Study Drug Due to Any Reason</title>
          <description>The premature discontinuation of study drug due to any reason</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Premature Discontinuation of Study Due to Any Reason</title>
        <description>|The premature discontinuation of study due to any reason</description>
        <time_frame>28 weeks (randomisation visit to last follow up visit)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD0837 150 mg</title>
            <description>AZD0837 150 mg</description>
          </group>
          <group group_id="O2">
            <title>AZD0837 300 mg</title>
            <description>AZD0837 300 mg</description>
          </group>
          <group group_id="O3">
            <title>Standard Therapy</title>
            <description>Standard Therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Premature Discontinuation of Study Due to Any Reason</title>
          <description>|The premature discontinuation of study due to any reason</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Compliance With Study Drug</title>
        <description>[(number of doses dispensed-number of doses returned)/number of days between visits]*100</description>
        <time_frame>24 weeks (randomisation visit to last treatment visit) according to protocol</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD0837 150 mg</title>
            <description>AZD0837 150 mg</description>
          </group>
          <group group_id="O2">
            <title>AZD0837 300 mg</title>
            <description>AZD0837 300 mg</description>
          </group>
          <group group_id="O3">
            <title>Standard Therapy</title>
            <description>Standard Therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Compliance With Study Drug</title>
          <description>[(number of doses dispensed-number of doses returned)/number of days between visits]*100</description>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.95" spread="16.503"/>
                    <measurement group_id="O2" value="99.82" spread="11.383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Compliance With Study Visits/Assessments</title>
        <description>(number of visits attended acroos the time of study divided by the number of expected visits according to the time of entry into study)*100</description>
        <time_frame>28 weeks (randomisation visit to last follow up visit) according to protocol</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD0837 150 mg</title>
            <description>AZD0837 150 mg</description>
          </group>
          <group group_id="O2">
            <title>AZD0837 300 mg</title>
            <description>AZD0837 300 mg</description>
          </group>
          <group group_id="O3">
            <title>Standard Therapy</title>
            <description>Standard Therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Compliance With Study Visits/Assessments</title>
          <description>(number of visits attended acroos the time of study divided by the number of expected visits according to the time of entry into study)*100</description>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.3" spread="15.01"/>
                    <measurement group_id="O2" value="95.6" spread="10.45"/>
                    <measurement group_id="O3" value="97.5" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bleeding Events</title>
        <description>Number of patients with a bleeding event while on study drug. Patients with multiple bleeding events are counted once</description>
        <time_frame>24 weeks (randomisation visit to last treatment visit) according to protocol. For patients who discontinued treatment the time frame was &lt;24 weeks. Mean number of weeks was 7 weeks (baseline to end of treatment visit)</time_frame>
        <population>41 + 42 + 45 participants were randomized into the study to treatment arm 1, arm 2 and arm 3 respectively. However, one of the participants randomized to arm 2 was treated according to treatment arm 3</population>
        <group_list>
          <group group_id="O1">
            <title>AZD0837 150 mg</title>
            <description>AZD0837 150 mg</description>
          </group>
          <group group_id="O2">
            <title>AZD0837 300 mg</title>
            <description>AZD0837 300 mg</description>
          </group>
          <group group_id="O3">
            <title>Standard Therapy</title>
            <description>Standard Therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Bleeding Events</title>
          <description>Number of patients with a bleeding event while on study drug. Patients with multiple bleeding events are counted once</description>
          <population>41 + 42 + 45 participants were randomized into the study to treatment arm 1, arm 2 and arm 3 respectively. However, one of the participants randomized to arm 2 was treated according to treatment arm 3</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Creatinine Level</title>
        <description>Individual change in Creatinine level (umil/L) from baseline to week 4 visit for patients while on study drug (week 4 visit-baseline)</description>
        <time_frame>4 weeks according to protocol (randomisation visit to week 4 visit)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD0837 150 mg</title>
            <description>AZD0837 150 mg</description>
          </group>
          <group group_id="O2">
            <title>AZD0837 300 mg</title>
            <description>AZD0837 300 mg</description>
          </group>
          <group group_id="O3">
            <title>Standard Therapy</title>
            <description>Standard Therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Creatinine Level</title>
          <description>Individual change in Creatinine level (umil/L) from baseline to week 4 visit for patients while on study drug (week 4 visit-baseline)</description>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" spread="8.64"/>
                    <measurement group_id="O2" value="3.6" spread="13.21"/>
                    <measurement group_id="O3" value="2.6" spread="12.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alanine Aminotransferase (ALAT)</title>
        <description>Number of patients while on study drug with Alanine aminotransferase (ALAT)&gt;=3 times upper limit of normal.</description>
        <time_frame>24 weeks (randomisation visit to last treatment visit) according to protocol. For patients who discontinued treatment the time frame was &lt;24 weeks. Mean number of weeks was 7 weeks (baseline to end of treatment visit)</time_frame>
        <population>41 + 42 + 45 participants were randomized into the study to treatment arm 1, arm 2 and arm 3 respectively. However, one of the participants randomized to arm 2 was treated according to treatment arm 3</population>
        <group_list>
          <group group_id="O1">
            <title>AZD0837 150 mg</title>
            <description>AZD0837 150 mg</description>
          </group>
          <group group_id="O2">
            <title>AZD0837 300 mg</title>
            <description>AZD0837 300 mg</description>
          </group>
          <group group_id="O3">
            <title>Standard Therapy</title>
            <description>Standard Therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Alanine Aminotransferase (ALAT)</title>
          <description>Number of patients while on study drug with Alanine aminotransferase (ALAT)&gt;=3 times upper limit of normal.</description>
          <population>41 + 42 + 45 participants were randomized into the study to treatment arm 1, arm 2 and arm 3 respectively. However, one of the participants randomized to arm 2 was treated according to treatment arm 3</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bilirubin</title>
        <description>Number of patients while on study drug with Bilirubin&gt;=2 times upper limit of normal.</description>
        <time_frame>24 weeks (randomisation visit to last treatment visit) according to protocol. For patients who discontinued treatment the time frame was &lt;24 weeks. Mean number of weeks was 7 weeks (baseline to end of treatment visit)</time_frame>
        <population>41 + 42 + 45 participants were randomized into the study to treatment arm 1, arm 2 and arm 3 respectively. However, one of the participants randomized to arm 2 was treated according to treatment arm 3</population>
        <group_list>
          <group group_id="O1">
            <title>AZD0837 150 mg</title>
            <description>AZD0837 150 mg</description>
          </group>
          <group group_id="O2">
            <title>AZD0837 300 mg</title>
            <description>AZD0837 300 mg</description>
          </group>
          <group group_id="O3">
            <title>Standard Therapy</title>
            <description>Standard Therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Bilirubin</title>
          <description>Number of patients while on study drug with Bilirubin&gt;=2 times upper limit of normal.</description>
          <population>41 + 42 + 45 participants were randomized into the study to treatment arm 1, arm 2 and arm 3 respectively. However, one of the participants randomized to arm 2 was treated according to treatment arm 3</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration of AZD0837 (Prodrug)</title>
        <description>Assessment of plasma concentration of AZD0837 (prodrug) made on the week 4 visit</description>
        <time_frame>4 weeks after baseline according to protocol</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD0837 150 mg</title>
            <description>AZD0837 150 mg</description>
          </group>
          <group group_id="O2">
            <title>AZD0837 300 mg</title>
            <description>AZD0837 300 mg</description>
          </group>
          <group group_id="O3">
            <title>Standard Therapy</title>
            <description>Standard Therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration of AZD0837 (Prodrug)</title>
          <description>Assessment of plasma concentration of AZD0837 (prodrug) made on the week 4 visit</description>
          <units>nmol/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="596.0" lower_limit="5.0" upper_limit="2920.0"/>
                    <measurement group_id="O2" value="636.0" lower_limit="18.2" upper_limit="5920.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration of AR-H067637XX (Active Metabolite)</title>
        <description>Assessment of plasma concentration of AR-H067637XX (active metabolite) made on the week 4 visit</description>
        <time_frame>4 weeks after baseline according to protocol</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD0837 150 mg</title>
            <description>AZD0837 150 mg</description>
          </group>
          <group group_id="O2">
            <title>AZD0837 300 mg</title>
            <description>AZD0837 300 mg</description>
          </group>
          <group group_id="O3">
            <title>Standard Therapy</title>
            <description>Standard Therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration of AR-H067637XX (Active Metabolite)</title>
          <description>Assessment of plasma concentration of AR-H067637XX (active metabolite) made on the week 4 visit</description>
          <units>nmol/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="258.5" lower_limit="5.0" upper_limit="539.0"/>
                    <measurement group_id="O2" value="368.5" lower_limit="159.0" upper_limit="776.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in D-Dimer Level</title>
        <description>Individual change in D-Dimer level (ng/ml) from baseline to week 4 visit for patients while on study drug (week 4 visit-baseline)</description>
        <time_frame>4 weeks according to protocol.(baseline to week 4 visit)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD0837 150 mg</title>
            <description>AZD0837 150 mg</description>
          </group>
          <group group_id="O2">
            <title>AZD0837 300 mg</title>
            <description>AZD0837 300 mg</description>
          </group>
          <group group_id="O3">
            <title>Standard Therapy</title>
            <description>Standard Therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Change in D-Dimer Level</title>
          <description>Individual change in D-Dimer level (ng/ml) from baseline to week 4 visit for patients while on study drug (week 4 visit-baseline)</description>
          <units>ng/ml</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.484" lower_limit="-78.37" upper_limit="288.13"/>
                    <measurement group_id="O2" value="-41.445" lower_limit="-92.61" upper_limit="130.00"/>
                    <measurement group_id="O3" value="4.853" lower_limit="-80.12" upper_limit="793.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Activated Partial Thromboplastin Time (APTT)</title>
        <description>Individual change in Activated partial thromboplastin time (APTT) (sec) from baseline to week 4 visit for patients while on study drug (week 4 visit-baseline)</description>
        <time_frame>4 weeks according to protocol.(baseline to week 4 visit)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD0837 150 mg</title>
            <description>AZD0837 150 mg</description>
          </group>
          <group group_id="O2">
            <title>AZD0837 300 mg</title>
            <description>AZD0837 300 mg</description>
          </group>
          <group group_id="O3">
            <title>Standard Therapy</title>
            <description>Standard Therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Activated Partial Thromboplastin Time (APTT)</title>
          <description>Individual change in Activated partial thromboplastin time (APTT) (sec) from baseline to week 4 visit for patients while on study drug (week 4 visit-baseline)</description>
          <units>sec</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.74" lower_limit="-17.8" upper_limit="105.8"/>
                    <measurement group_id="O2" value="51.51" lower_limit="3.1" upper_limit="75.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ecarin Clotting Time (ECT)</title>
        <description>Individual change in Ecarin clotting time (ECT) (sec) from baseline to week 4 visit for patients while on study drug (week 4 visit-baseline)</description>
        <time_frame>4 weeks according to protocol.(baseline to week 4 visit)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD0837 150 mg</title>
            <description>AZD0837 150 mg</description>
          </group>
          <group group_id="O2">
            <title>AZD0837 300 mg</title>
            <description>AZD0837 300 mg</description>
          </group>
          <group group_id="O3">
            <title>Standard Therapy</title>
            <description>Standard Therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Ecarin Clotting Time (ECT)</title>
          <description>Individual change in Ecarin clotting time (ECT) (sec) from baseline to week 4 visit for patients while on study drug (week 4 visit-baseline)</description>
          <units>sec</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125.6" lower_limit="6" upper_limit="274"/>
                    <measurement group_id="O2" value="179.1" lower_limit="7" upper_limit="341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>41 + 42 + 45 participants were randomized into the study to treatment arm 1, arm 2 and arm 3 respectively. However, one of the participants randomized to arm 2 was treated according to treatment arm 3</desc>
      <group_list>
        <group group_id="E1">
          <title>AZD0837 150 mg</title>
          <description>AZD0837 150 mg</description>
        </group>
        <group group_id="E2">
          <title>AZD0837 300 mg</title>
          <description>AZD0837 300 mg</description>
        </group>
        <group group_id="E3">
          <title>Standard Therapy</title>
          <description>Standard Therapy</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Drug Intolerance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Podagra</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <phone>+44 1509 645895</phone>
      <email>aztrial_results_posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

